



Thursday 8 December 2022, 16h CET

Facing FDA's regulatory issues for targeted agents in oncology.

Dr. Kay NOEL

Dr. Kay Noel has over 30 years' experience in pharmaceutical development, with 12 NDA approvals. Previous successful start-up and product development experiences include creation of the first healthcare business plan, managing a \$75 million financing, and development and marketing of the first PCR kits at Cetus Corporation; Co-founder and Vice President, Planning & Commercial Development for a novel oncology drug distribution system called Oncology Therapeutics Network, subsequently sold to Bristol Myers Squibb; and Co-founder and Chief Operating Officer of Oncoethix SA, a cancer drug development company, subsequently sold to Merck in 2014. She currently serves as a regulatory consultant to several companies developing targeted agents in oncology. Dr. Noel has a PhD in biophysics from the University of Michigan (USA).

